Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2021

01.07.2021 | Epidemiology

Medication use and mammographic breast density

verfasst von: Yunan Han, Chee Teik Lee, Shuai Xu, Xiaoyue Mi, Courtnie R. Phillip, Ana S. Salazar, Malika Rakhmankulova, Adetunji T. Toriola

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A dense breast on mammogram is a strong risk factor for breast cancer. Identifying factors that reduce mammographic breast density could thus provide insight into breast cancer prevention. Due to the limited number of studies and conflicting findings, we investigated the associations of medication use (specifically statins, aspirin, and ibuprofen) with mammographic breast density.

Methods

We evaluated these associations in 775 women who were recruited during an annual screening mammogram at Washington University School of Medicine, St. Louis. We measured mammographic breast density using Volpara. We used multivariable-adjusted linear regressions to determine the associations of medication use (statins, aspirin, and ibuprofen) with mammographic breast density. Least squared means were generated and back-transformed for easier interpretation.

Results

The mean age of study participants was 52.9 years. Statin use in the prior 12 months was not associated with volumetric percent density or dense volume, but was positively associated with non-dense volume. The mean volumetric percent density was 8.6% among statin non-users, 7.2% among women who used statins 1–3 days/week, and 7.3% among women who used statins ≥ 4 days/week (p trend = 0.07). The non-dense volume was 1297.1 cm3 among statin non-users, 1368.7 cm3 among women who used statins 1–3 days/week, and 1408.4 cm3 among those who used statins ≥ 4 days/week (p trend = 0.02). We did not observe statistically significant differences in mammographic breast density by aspirin or ibuprofen use.

Conclusion

Statin, aspirin, and ibuprofen use was not associated with volumetric percent density and dense volume, but statin use was positively associated with non-dense volume. Any potential associations of these medications with breast cancer risk are unlikely to be mediated through an effect on volumetric percent density.
Literatur
1.
Zurück zum Zitat Boyd NF et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236CrossRef Boyd NF et al (2007) Mammographic density and the risk and detection of breast cancer. N Engl J Med 356(3):227–236CrossRef
2.
Zurück zum Zitat Nazari SS, Mukherjee P (2018) An overview of mammographic density and its association with breast cancer. Breast Cancer 25(3):259–267CrossRef Nazari SS, Mukherjee P (2018) An overview of mammographic density and its association with breast cancer. Breast Cancer 25(3):259–267CrossRef
3.
Zurück zum Zitat McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169CrossRef McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169CrossRef
4.
Zurück zum Zitat Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629CrossRef Byrne C et al (1995) Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 87(21):1622–1629CrossRef
5.
Zurück zum Zitat Boyd NF et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6(10):798–808CrossRef Boyd NF et al (2005) Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 6(10):798–808CrossRef
6.
Zurück zum Zitat Bond-Smith D, Stone J (2019) Methodological challenges and updated findings from a meta-analysis of the association between mammographic density and breast cancer. Cancer Epidemiol Biomarkers Prev 28(1):22–31CrossRef Bond-Smith D, Stone J (2019) Methodological challenges and updated findings from a meta-analysis of the association between mammographic density and breast cancer. Cancer Epidemiol Biomarkers Prev 28(1):22–31CrossRef
7.
Zurück zum Zitat Engmann NJ et al (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236CrossRef Engmann NJ et al (2017) Population-attributable risk proportion of clinical risk factors for breast cancer. JAMA Oncol 3(9):1228–1236CrossRef
8.
Zurück zum Zitat Boudreau DM, Rutter CM, Buist DS (2006) The influence of statin use on breast density. Cancer Epidemiol Biomark Prev 15(5):1026–1029CrossRef Boudreau DM, Rutter CM, Buist DS (2006) The influence of statin use on breast density. Cancer Epidemiol Biomark Prev 15(5):1026–1029CrossRef
9.
Zurück zum Zitat Higgins MJ et al (2012) A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131(3):915–924CrossRef Higgins MJ et al (2012) A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat 131(3):915–924CrossRef
10.
Zurück zum Zitat Ji Y et al (2016) The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prev Res (Phila) 9(5):379–384CrossRef Ji Y et al (2016) The effect of atorvastatin on breast cancer biomarkers in high-risk women. Cancer Prev Res (Phila) 9(5):379–384CrossRef
11.
Zurück zum Zitat Vinayak S et al (2013) A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 142(2):389–398CrossRef Vinayak S et al (2013) A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Res Treat 142(2):389–398CrossRef
12.
Zurück zum Zitat Skarping I et al (2015) Effects of statin use on volumetric mammographic density: results from the KARMA study. BMC Cancer 15:435CrossRef Skarping I et al (2015) Effects of statin use on volumetric mammographic density: results from the KARMA study. BMC Cancer 15:435CrossRef
13.
Zurück zum Zitat Stone J et al (2012) The association between mammographic density measures and aspirin or other NSAID use. Breast Cancer Res Treat 132(1):259–266CrossRef Stone J et al (2012) The association between mammographic density measures and aspirin or other NSAID use. Breast Cancer Res Treat 132(1):259–266CrossRef
14.
Zurück zum Zitat McTiernan A et al (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18(5):1524–1530CrossRef McTiernan A et al (2009) No effect of aspirin on mammographic density in a randomized controlled clinical trial. Cancer Epidemiol Biomarkers Prev 18(5):1524–1530CrossRef
15.
Zurück zum Zitat Maskarinec G et al (2008) Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 112(1):133–139CrossRef Maskarinec G et al (2008) Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 112(1):133–139CrossRef
16.
Zurück zum Zitat Terry MB et al (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(5):1088–1095CrossRef Terry MB et al (2008) Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(5):1088–1095CrossRef
17.
Zurück zum Zitat Wood ME et al (2017) Aspirin use is associated with lower mammographic density in a large screening cohort. Breast Cancer Res Treat 162(3):419–425CrossRef Wood ME et al (2017) Aspirin use is associated with lower mammographic density in a large screening cohort. Breast Cancer Res Treat 162(3):419–425CrossRef
18.
Zurück zum Zitat Ahern TP et al (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15(10):e461–e468CrossRef Ahern TP et al (2014) Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol 15(10):e461–e468CrossRef
19.
Zurück zum Zitat Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444–449CrossRef Agrawal A, Fentiman IS (2008) NSAIDs and breast cancer: a possible prevention and treatment strategy. Int J Clin Pract 62(3):444–449CrossRef
20.
Zurück zum Zitat Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192CrossRef Khuder SA, Mutgi AB (2001) Breast cancer and NSAID use: a meta-analysis. Br J Cancer 84(9):1188–1192CrossRef
21.
Zurück zum Zitat Bucher HC, Griffith LE, Guyatt GH (1998) Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128(2):89–95CrossRef Bucher HC, Griffith LE, Guyatt GH (1998) Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. Ann Intern Med 128(2):89–95CrossRef
22.
Zurück zum Zitat Hebert PR et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. Overv Randomized Trials JAMA 278(4):313–321 Hebert PR et al (1997) Cholesterol lowering with statin drugs, risk of stroke, and total mortality. Overv Randomized Trials JAMA 278(4):313–321
23.
Zurück zum Zitat Bjarnadottir O, Romero Q, Bendahl PO, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138(2):499–508. https://doi.org/10.1007/s10549-013-2473-6 (Epub 2013 Mar 8 PMID: 23471651)CrossRefPubMed Bjarnadottir O, Romero Q, Bendahl PO, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S (2013) Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 138(2):499–508. https://​doi.​org/​10.​1007/​s10549-013-2473-6 (Epub 2013 Mar 8 PMID: 23471651)CrossRefPubMed
24.
Zurück zum Zitat Zhang X et al (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 30(28):3468–3477CrossRef Zhang X et al (2012) Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 30(28):3468–3477CrossRef
25.
Zurück zum Zitat Lee HN, Sohn Y-M, Han KH (2015) Comparison of mammographic density estimation by Volpara software with radiologists’ visual assessment: analysis of clinical–radiologic factors affecting discrepancy between them. Acta Radiol 56(9):1061–1068CrossRef Lee HN, Sohn Y-M, Han KH (2015) Comparison of mammographic density estimation by Volpara software with radiologists’ visual assessment: analysis of clinical–radiologic factors affecting discrepancy between them. Acta Radiol 56(9):1061–1068CrossRef
26.
Zurück zum Zitat Ko SY et al (2014) Mammographic density estimation with automated volumetric breast density measurement. Korean J Radiol 15(3):313–321CrossRef Ko SY et al (2014) Mammographic density estimation with automated volumetric breast density measurement. Korean J Radiol 15(3):313–321CrossRef
27.
Zurück zum Zitat Gubern-Mérida A et al (2014) Volumetric breast density estimation from full-field digital mammograms: a validation study. PLoS ONE 9(1):e85952CrossRef Gubern-Mérida A et al (2014) Volumetric breast density estimation from full-field digital mammograms: a validation study. PLoS ONE 9(1):e85952CrossRef
28.
Zurück zum Zitat Wang J et al (2013) Agreement of mammographic measures of volumetric breast density to MRI. PLoS ONE 8(12):e81653CrossRef Wang J et al (2013) Agreement of mammographic measures of volumetric breast density to MRI. PLoS ONE 8(12):e81653CrossRef
29.
Zurück zum Zitat Alonzo-Proulx O et al (2015) Reliability of automated breast density measurements. Radiology 275(2):366–376CrossRef Alonzo-Proulx O et al (2015) Reliability of automated breast density measurements. Radiology 275(2):366–376CrossRef
30.
Zurück zum Zitat Han Y et al (2019) Milk intake and mammographic density in premenopausal women. Breast Cancer Res Treat 174(1):249–255CrossRef Han Y et al (2019) Milk intake and mammographic density in premenopausal women. Breast Cancer Res Treat 174(1):249–255CrossRef
32.
Zurück zum Zitat Brandt KR et al (2019) Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer. Breast Cancer Res 21(1):118CrossRef Brandt KR et al (2019) Automated volumetric breast density measures: differential change between breasts in women with and without breast cancer. Breast Cancer Res 21(1):118CrossRef
33.
Zurück zum Zitat Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH et al (2016) Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. Radiology 279(3):710–719CrossRef Brandt KR, Scott CG, Ma L, Mahmoudzadeh AP, Jensen MR, Whaley DH et al (2016) Comparison of clinical and automated breast density measurements: implications for risk prediction and supplemental screening. Radiology 279(3):710–719CrossRef
34.
Zurück zum Zitat Gaudette É et al (2015) Do statins reduce the health and health care costs of obesity? Pharmacoeconomics 33(7):723–734CrossRef Gaudette É et al (2015) Do statins reduce the health and health care costs of obesity? Pharmacoeconomics 33(7):723–734CrossRef
35.
Zurück zum Zitat Cauley JA et al (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8):749–756CrossRef Cauley JA et al (2003) Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 12(8):749–756CrossRef
36.
Zurück zum Zitat McTiernan A et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol 27(36):6135–6143CrossRef McTiernan A et al (2009) Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women’s health initiative randomized trial. J Clin Oncol 27(36):6135–6143CrossRef
37.
Zurück zum Zitat Campbell MJ et al (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714CrossRef Campbell MJ et al (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714CrossRef
38.
Zurück zum Zitat Anothaisintawee T et al (2016) Effect of lipophilic and hydrophilic statins on breast cancer risk in thai women: a cross-sectional study. J Cancer 7(9):1163–1168CrossRef Anothaisintawee T et al (2016) Effect of lipophilic and hydrophilic statins on breast cancer risk in thai women: a cross-sectional study. J Cancer 7(9):1163–1168CrossRef
39.
Zurück zum Zitat Mansourian M et al (2016) Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies. J Pharm Pharm Sci 19(1):72–81CrossRef Mansourian M et al (2016) Statins use and risk of breast cancer recurrence and death: a systematic review and meta-analysis of observational studies. J Pharm Pharm Sci 19(1):72–81CrossRef
40.
Zurück zum Zitat Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833–843CrossRef Browning DR, Martin RM (2007) Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120(4):833–843CrossRef
41.
Zurück zum Zitat Islam MM et al (2017) Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 296(6):1043–1053CrossRef Islam MM et al (2017) Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 296(6):1043–1053CrossRef
42.
Zurück zum Zitat Van Wyhe RD, Rahal OM, Woodward WA (2017) Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer (Dove Med Press) 9:559–565 Van Wyhe RD, Rahal OM, Woodward WA (2017) Effect of statins on breast cancer recurrence and mortality: a review. Breast Cancer (Dove Med Press) 9:559–565
Metadaten
Titel
Medication use and mammographic breast density
verfasst von
Yunan Han
Chee Teik Lee
Shuai Xu
Xiaoyue Mi
Courtnie R. Phillip
Ana S. Salazar
Malika Rakhmankulova
Adetunji T. Toriola
Publikationsdatum
01.07.2021
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2021
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-021-06321-5

Weitere Artikel der Ausgabe 2/2021

Breast Cancer Research and Treatment 2/2021 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.